The FY22 PCARP Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must function as a research scientist and the other partner as a clinician investigator. It should be clear that both have had equal intellectual input in the design of the research project. Projects involving convergence science partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care. Inclusion of experts from outside the pancreatic cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Full support for large-scale clinical trials is not expected; retrospective tissue analysis, correlative studies, or small pilot clinical trials are permitted.
Deadlines:
To be considered for funding, applications for the FY22 PCARP Translational Research Partnership Award must address at least one of the FY22 PCARP Focus Areas:
The anticipated direct costs budgeted for the entire period of performance for an FY22 Pancreatic Cancer Translational Research Partnership Award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
